NPR’s Ayesha Rascoe speaks with College of Michigan Legislation Professor Nicholas Bagley concerning the lawsuits filed by pharmaceutical teams to strike down Medicare’s new drug negotiating energy.
AYESHA RASCOE, HOST:
It has been only a few days because the Division of Well being and Human Providers introduced the primary 10 medicine that Medicare will instantly negotiate costs for. However in courts throughout the nation, pharmaceutical teams are already suing the Biden administration, attempting to invalidate the brand new program. Nicholas Bagley focuses on well being regulation on the College of Michigan. Beforehand, he was chief counsel to Governor Gretchen Whitmer, Democrat of Michigan. Welcome to the present.
NICHOLAS BAGLEY: I am glad to be right here. Thanks for having me.
RASCOE: This push to barter cheaper drug costs – like, remind us, why is the federal government in a position to do that and why is that this solely taking place now? Individuals might need thought they’d have been in a position to do that earlier than.
BAGLEY: Yeah, effectively, keep in mind – forged your thoughts again about 20 years – Medicare truly did not initially cowl pharmaceuticals in any respect. And pharmaceuticals had been added to Medicare as a profit solely in 2003. And as a part of that value for getting that protection over the end line, Republican legislators insisted that Medicare not have the authority to individually negotiate the costs for medicine. Negotiations would as a substitute be dealt with by particular person prescription drug plans that individuals would enroll in. And there have been numerous issues that this was, you recognize, leaving Medicare’s bargaining energy to 1 aspect and primarily kneecapping the federal authorities and attempting to get an excellent value for taxpayers for these medicine.
RASCOE: So about these lawsuits which can be happening now, about what number of lawsuits are there and who’s driving them?
BAGLEY: There are eight of them as of now. They usually’re primarily pushed by the pharmaceutical firms whose medicine have been recognized for negotiation. So these are firms which can be saying, look, we would favor to maintain promoting our medicine on the costs that we have, you recognize, bought them for prior to now. We do not need to enter into these value negotiations. And we consider that the regulation requiring us to take action – successfully, requiring us to take action – is unconstitutional.
RASCOE: Effectively, what is the argument?
BAGLEY: They’re making a bunch of various sorts of constitutional claims. It is – you recognize, I name it throwing constitutional spaghetti on the wall to see what sticks. However the core of their argument is that it is Medicare demanding that drug producers cut back their costs. It is truly not a negotiation. It is a set of value controls. They usually say these value controls violate their rights in a few other ways. They are saying that the costs are going to be so low that they successfully take their medicine with out simply compensation. And that is prohibited underneath the Fifth Modification of the Structure.
Additionally they say that they are compelled to enter this stuff which can be referred to as negotiations. They usually say, effectively, we do not suppose these are actually negotiations in any respect. We’re being coerced, and we do not suppose these costs are going to be truthful. And so due to this fact, you are compelling us to make statements that we predict are unfaithful. There are different constitutional claims too, however these are those that seem in all the lawsuits and those which have gotten probably the most consideration up to now.
RASCOE: Is there a case to be made that that is the federal government, that possibly you do not have numerous recourse or that it is not a good negotiation?
BAGLEY: Yeah, from the drug firms’ perspective, that is going to really feel like numerous strain. As a result of as a way to keep away from the decrease costs for his or her medicine, they are going to should withdraw from the Medicare and Medicaid program altogether. In different phrases, what Medicare is saying is, hear, if you wish to promote us considered one of your medicine, we will insist on what we predict is a good value. And for those who do not prefer it, you must stroll away altogether. And there is some huge cash coming from Medicare and Medicaid into drug firms’ pockets, and they are going to suppose twice earlier than stepping away. And in order that from their perspective, it certain seems like coercion within the sense that they do not really feel like they’ve a selection.
However – and that is actually an vital level – simply because the Medicare and Medicaid applications are so profitable, it does not imply that the drug producers are being coerced into taking part. So for them to say that that is someway a value management and that they are someway bereft of any free selection, effectively, that is a consequence of simply how lavishly we spend for pharmaceuticals. It would not rely as coercion. It definitely would not rely coercion underneath the regulation.
RASCOE: With all of this authorized wrangling, although, it looks as if that is the type of factor which may find yourself on the Supreme Courtroom. Is the federal government on strong authorized floor? Or may the Supreme Courtroom strike this down the best way they struck down, say the Biden plan to discharge federal pupil mortgage debt for thousands and thousands of People?
BAGLEY: It is a good query. And definitely, the drug producers are hoping to take this case as much as the Supreme Courtroom. I also needs to add that, you recognize, just like the Biden administration’s pupil mortgage reduction program, that was an govt department motion. And when the chief department strikes to implement federal regulation, these selections are sometimes topic to fairly intensive court docket scrutiny. On this case, the drug firms are difficult the constitutionality of an act of Congress. These are a lot more durable to win. May the Supreme Courtroom settle for the drug producers’ invitation to work a reasonably radical change within the regulation? It is attainable. I do not see any motive to suppose that is seemingly. You understand, this is not a large push to vary the regulation coming from all organs of the Republican Celebration political institution. This can be a bunch of drug firms which can be upset about Medicare value negotiation. And to be sincere, the place they’re pushing is just not fashionable amongst Democrats or Republicans.
RASCOE: That is Nicholas Bagley, regulation professor on the College of Michigan. Thanks a lot for becoming a member of us.
BAGLEY: Thanks for having me.
(SOUNDBITE OF JON HOPKINS’ “LOST IN THOUGHT”)
Copyright © 2023 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional info.
NPR transcripts are created on a rush deadline by an NPR contractor. This textual content might not be in its closing kind and could also be up to date or revised sooner or later. Accuracy and availability might fluctuate. The authoritative document of NPR’s programming is the audio document.
